Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 234

1.

Colorectal Cancer-Associated Spontaneous Tumor Lysis Syndrome: a Case Report and Review of the Current Literature.

Kearney MR, Chen EY, Stenzel P, Corless CL, Deloughery TG, Zivney M, Lopez CD.

J Gastrointest Cancer. 2018 Apr 25. doi: 10.1007/s12029-018-0102-7. [Epub ahead of print] No abstract available.

PMID:
29691710
2.

Gastrointestinal stromal tumours of the oesophagus: a clinicopathological and molecular analysis of 27 cases.

Kang G, Kang Y, Kim KH, Ha SY, Kim JY, Shim YM, Heinrich MC, Kim KM, Corless CL.

Histopathology. 2017 Nov;71(5):805-812. doi: 10.1111/his.13292. Epub 2017 Sep 6.

PMID:
28644569
3.

Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions.

Gay ND, Wang Y, Beadling C, Warrick A, Neff T, Corless CL, Tolba K.

J Thorac Oncol. 2017 Aug;12(8):e107-e110. doi: 10.1016/j.jtho.2017.04.025. Epub 2017 May 10. No abstract available.

4.

Defining the Impact of Adjuvant Therapy in Molecularly Defined Subsets of Gastrointestinal Stromal Tumor : From Lumping to Splitting.

Heinrich MC, Corless CL, Demetri GD.

JAMA Oncol. 2017 May 1;3(5):597-599. doi: 10.1001/jamaoncol.2016.5740. No abstract available.

PMID:
28334361
5.

Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors.

Bannon AE, Klug LR, Corless CL, Heinrich MC.

Expert Rev Mol Diagn. 2017 May;17(5):445-457. doi: 10.1080/14737159.2017.1308826. Epub 2017 Mar 27. Review.

PMID:
28317407
6.

MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.

Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Mariño-Enríquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA.

Nat Commun. 2017 Mar 8;8:14674. doi: 10.1038/ncomms14674.

7.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.

JAMA Oncol. 2017 Jul 1;3(7):944-952. doi: 10.1001/jamaoncol.2016.6728.

8.

FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.

Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, Madlensky L, Heestand GM, Trent JC, Kurzrock R, Morosini D, Ross JS, Harismendy O, Sicklick JK.

J Transl Med. 2016 Dec 14;14(1):339.

9.

Next-Generation Sequencing in Cancer Diagnostics.

Corless CL.

J Mol Diagn. 2016 Nov;18(6):813-816. doi: 10.1016/j.jmoldx.2016.08.002. Epub 2016 Sep 21.

PMID:
27664753
10.

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S.

Ann Oncol. 2016 Sep;27(9):1794-9. doi: 10.1093/annonc/mdw228. Epub 2016 Jul 1.

PMID:
27371698
11.

IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma.

Svalina MN, Kikuchi K, Abraham J, Lal S, Davare MA, Settelmeyer TP, Young MC, Peckham JL, Cho YJ, Michalek JE, Hernandez BS, Berlow NE, Jackson M, Guillaume DJ, Selden NR, Bigner DD, Nazemi KJ, Green SC, Corless CL, Gultekin S, Mansoor A, Rubin BP, Woltjer R, Keller C.

Sci Rep. 2016 Jun 3;6:27012. doi: 10.1038/srep27012.

12.

Discordant Mutations in Paired Primary and Metastatic Endometrial Adenocarcinomas Identified by Semiconductor-Based Sequencing for Rapid Cancer Genotyping.

Bergstrom CP, Geest K, O'Gara R, Corless CL, Morgan TK.

Reprod Sci. 2016 Nov;23(11):1575-1579. Epub 2016 May 11.

13.

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.

Wagner AJ, Agulnik M, Heinrich MC, Mahadevan D, Riedel RF, von Mehren M, Trent J, Demetri GD, Corless CL, Yule M, Lyons JF, Oganesian A, Keer H.

Eur J Cancer. 2016 Jul;61:94-101. doi: 10.1016/j.ejca.2016.03.076. Epub 2016 May 5.

14.

A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing.

Beadling C, Wald AI, Warrick A, Neff TL, Zhong S, Nikiforov YE, Corless CL, Nikiforova MN.

J Mol Diagn. 2016 Mar;18(2):165-75. doi: 10.1016/j.jmoldx.2015.10.002. Epub 2015 Dec 30.

PMID:
26747586
15.

Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-mutated gastrointestinal stromal tumors.

Patil DT, Ma S, Konishi M, Carver PD, Pukay M, Beadling C, Corless CL, Rubin BP.

Am J Clin Pathol. 2015 Nov;144(5):782-9. doi: 10.1309/AJCPRK3V2EIIUPQZ.

PMID:
26486743
16.

SDHC methylation in gastrointestinal stromal tumors (GIST): a case report.

Urbini M, Astolfi A, Indio V, Heinrich MC, Corless CL, Nannini M, Ravegnini G, Biasco G, Pantaleo MA.

BMC Med Genet. 2015 Sep 28;16:87. doi: 10.1186/s12881-015-0233-7.

17.

Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.

Hahn NM, Knudsen BS, Daneshmand S, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Liu Z, Breen T, Fleming MT, Lance R, Corless CL, Alva AS, Shen SS, Huang F, Gertych A, Gallick GE, Mallick J, Ryan C, Galsky MD, Lerner SP, Posadas EM, Sonpavde G.

Urol Oncol. 2016 Jan;34(1):4.e11-7. doi: 10.1016/j.urolonc.2015.08.005. Epub 2015 Sep 9.

PMID:
26362343
18.

Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.

Butler TM, Johnson-Camacho K, Peto M, Wang NJ, Macey TA, Korkola JE, Koppie TM, Corless CL, Gray JW, Spellman PT.

PLoS One. 2015 Aug 28;10(8):e0136407. doi: 10.1371/journal.pone.0136407. eCollection 2015.

19.

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR Jr, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD.

J Clin Oncol. 2015 Aug 20;33(24):2617-22. doi: 10.1200/JCO.2014.60.2219. Epub 2015 May 11.

20.

Hybrid Capture 2 is as effective as PCR testing for high-risk human papillomavirus in head and neck cancers.

Hooper JE, Hebert JF, Schilling A, Gross ND, Schindler JS, Lagowski JP, Kulesz-Martin M, Corless CL, Morgan TK.

Appl Immunohistochem Mol Morphol. 2015 Apr;23(4):266-72. doi: 10.1097/PDM.0000000000000036.

Supplemental Content

Loading ...
Support Center